BAP1 and neoplasm: The value of retrospective analysis of clinical trials based on the genomic landscape has clearly been demonstrated in the past (Lynch et al., 2004) and we wait with interest whether this will be performed on archived tumour tissue, in the context of BAP1 status, from previous trials.